Pfizer’s MFN deal, new trial paradigm & TCG X’s $1.3B fund — a BioCentury podcast

How one pharma’s deal with the White House sets a precedent for presidents to negotiate drug pricing. Plus: IITs in the U.S. and investing in troubled waters

The short-term consequences for Pfizer from its “most favored nation” drug pricing deal with the White House are negligible, but the long-term effects on the industry could be profound and permanent.

On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses why the deal by Pfizer Inc. (NYSE:PFE) changes everything — and nothing — and what’s next in wrangling over drug pricing between industry and the Trump administration. 

The analysts also discuss PDUFA negotiations between FDA and leaders of BIO and PhRMA, how multi-site IITs could help bridge the academia-industry gap, and how TCG X plans to deploy its new $1.3 billion fund.